Focused On-demand Library for Interferon gamma

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P01579

UPID:

IFNG_HUMAN

Alternative names:

Immune interferon

Alternative UPACC:

P01579; B5BU88; Q53ZV4

Background:

Interferon gamma, also known as immune interferon, is a critical cytokine produced by T-cells and NK cells. It plays pivotal roles in antimicrobial, antiviral, and antitumor responses, primarily signaling through the JAK-STAT pathway. This protein is instrumental in activating immune cells, enhancing antigen presentation, and regulating gene expression to drive a robust immune response.

Therapeutic significance:

Interferon gamma's involvement in diseases such as Aplastic anemia and Immunodeficiency 69 highlights its therapeutic potential. Its role in enhancing antigen presentation and modulating immune responses suggests that targeting this cytokine could lead to innovative treatments for these conditions. Understanding the role of Interferon gamma could open doors to potential therapeutic strategies.